Soligenix

339 articles with Soligenix

• Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer

  8/28/2019

  Final topline results remain on target for first half 2020

• Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications

  8/15/2019

  Soligenix, Inc. announced that the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health, has awarded Soligenix a Phase I Small Business Innovation Research of approximately $150,000 to support the evaluation of SGX942 in pediatric indications.

• Soligenix Announces Recent Accomplishments And Second Quarter 2019 Financial Results

  8/13/2019

  Announced today its recent accomplishments and financial results for the quarter ended June 30, 2019.

• 2019 Colorado Protein Stability Conference Posters Now Available

  8/4/2019

  The two posters outlining ongoing formulation efforts to develop a trivalent thermostabilized Ebola vaccine presented on Wednesday July 31 at the 2019 Colorado Protein Stability Conference are now available.

• Soligenix Announces Conference Presentations Demonstrating Formulations of Single and Multivalent Ebola Subunit Vaccines

  7/31/2019

  Soligenix, Inc. announced that two posters outlining ongoing formulation efforts to develop a trivalent thermostabilized Ebola vaccine will be presented on Wednesday July 31 at the 2019 Colorado Protein Stability Conference in Breckenridge, CO.

• Soligenix Receives European Patents for Oral BDP in the Treatment of Acute Radiation Injury of the Gastrointestinal Tract

  7/29/2019

  Patents cover SGX201 in acute radiation enteritis and OrbeShield® for acute total body irradiation

• Soligenix Announces Appointment of Diane L. Parks to its Board of Directors

  7/8/2019

  Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced the appointment of Ms. Diane L. Parks to its Board of Directors.

• Soligenix to Present RiVax® Program at the 13ᵗʰ Annual CounterACT Network Research Symposium

  6/13/2019

  Soligenix, Inc. announced that Dr. Oreola Donini, Chief Scientific Officer, will be presenting data from the ricin toxin vaccine (RiVax®) program describing development of the vaccine under the Food and Drug Administration (FDA) Animal Rule.

• Soligenix Announces $600,000 Subaward Supporting Evaluation of Innate Defense Regulator Platform Technology as a Medical Countermeasure for Bacterial Threat Agents - May 28, 2019

  5/28/2019

  Soligenix, Inc. announced that Soligenix will be participating in a biodefense contract for the development of medical countermeasures against bacterial threat agents, with Soligenix awarded a subcontract of approximately $600,000 over 3 years.

• Soligenix Announces $600,000 Subaward Supporting Evaluation of Innate Defense Regulator Platform Technology as a Medical Countermeasure for Bacterial Threat Agents

  5/28/2019

  Soligenix, Inc. announced that Soligenix will be participating in a biodefense contract for the development of medical countermeasures against bacterial threat agents, with Soligenix awarded a subcontract of approximately $600,000 over 3 years.

• Soligenix Announces Recent Accomplishments And First Quarter 2019 Financial Results

  5/14/2019

  Soligenix, Inc. announced its recent accomplishments and financial results for the quarter ended March 31, 2019.

• Soligenix Announces Recent Accomplishments And First Quarter 2019 Financial Results - May 14, 2019

  5/14/2019

  Soligenix, Inc. announced its recent accomplishments and financial results for the quarter ended March 31, 2019.

• Dr. Christopher J. Schaber's Interview with The Wall Street Analyzer

  5/7/2019

  In this interview, Dr. Christopher J. Schaber, President and CEO, discusses the Company with The Wall Street Analyzer.

• Soligenix - Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials - April 23, 2019

  4/23/2019

  Soligenix, Inc. issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.

• Soligenix -- Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials

  4/23/2019

  Company provides Q1 2019 update and guidance

• Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial of SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer

  4/18/2019

  Enrollment Sufficient to Support the Interim Efficacy Analysis

• Soligenix Receives $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

  4/15/2019

  Soligenix, Inc. announced that it has received approximately $611,000, net of transaction costs, in non-dilutive financing via the state of New Jersey's Technology Business Tax Certificate Transfer Program.

• Soligenix and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for SGX942

  4/9/2019

  Acceptance of Pediatric Investigation Plan is important milestone on the path to submission of Marketing Authorization Application in Europe

• Soligenix Receives US Patent for Dusquetide Related Analogs

  4/4/2019

  Patent broadens protection in infectious disease and oral mucositis, including composition of matter claims

• Soligenix Announces Recent Accomplishments and Year-End 2018 Financial Results

  3/26/2019

  Soligenix, Inc. announced its recent accomplishments and financial results for the year ended December 31, 2018.